The Latest Breaking News from PHGE

BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review

BiomX Inc. (NYSE:PHGE) on Tuesday announced that the U.S. Food and Drug Administration (FDA) is continuing its evaluation of the nebulizer device used for drug administration in the company's Phase 2b trial of BX004 in cystic fibrosis patients.

Benzinga · Nov 26, 2025

BiomX Slashes Its Workforce By 50%, Atopic Dermatitis Program To Be Delayed

BiomX Inc (NYSE:PHGE) announced a corporate restructuring plan to focus its resources and extend the cash runway. The company had $55.7 million in cash, cash equivalents, short-term deposits, and a $15 million debt facility as of March 31. The restructuring will extend the company's capital resources at least until the middle of 2024. …

Benzinga · May 24, 2022